From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection (ctDNALung-Detect)
Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY
ctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥ 18 years;
• Ability to provide written informed consent;
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
• T1-T4 (T3,T4 multifocal) N0M0 NSCLC who are planned for complete surgical resection;
• Tumour size must be at least 1 cm (unidimensional) and have at least some solid component on imaging;
• Surgical tumour formalin-fixed, paraffin-embedded (FFPE) specimens for ctDNA studies are required.
Locations
Other Locations
Canada
Michael Garron Hospital
RECRUITING
Toronto
St. Joseph's Health Centre
RECRUITING
Toronto
University Health Network
RECRUITING
Toronto
Contact Information
Primary
Mary Rabey
mary.rabey@uhn.ca
416-946-4501
Time Frame
Start Date: 2021-07-06
Estimated Completion Date: 2027-03-30
Participants
Target number of participants: 360
Related Therapeutic Areas
Sponsors
Leads: University Health Network, Toronto
Collaborators: Ontario Institute for Cancer Research, The Princess Margaret Cancer Foundation